Holen Sie sich die Stockscreener-App
0.34
7.10%
-0.026
Handel nachbörslich:
.35
0.010
+2.94%
Schlusskurs vom Vortag:
$0.366
Offen:
$0.3785
24-Stunden-Volumen:
4.65M
Relative Volume:
0.54
Marktkapitalisierung:
$39.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.11M
KGV:
-0.5231
EPS:
-0.65
Netto-Cashflow:
$-26.55M
1W Leistung:
+9.68%
1M Leistung:
-50.89%
6M Leistung:
-12.80%
1J Leistung:
-81.82%
1-Tages-Spanne:
$0.3374
$0.39
1-Wochen-Bereich:
$0.2935
$0.39
52-Wochen-Spanne:
$0.25
$2.15
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Firmenname
Reviva Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
(408) 501-8881
Adresse
10080 N WOLFE ROAD, CUPERTINO
Vergleichen Sie RVPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.34 | 42.77M | 0 | -27.11M | -26.55M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-09-20 | Eingeleitet | ROTH MKM | Buy |
| 2023-06-08 | Eingeleitet | The Benchmark Company | Speculative Buy |
| 2022-01-24 | Eingeleitet | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Aktie (RVPH) Neueste Nachrichten
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock deliver sustainable ROEQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - ulpravda.ru
Is Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock a top pick in earnings seasonJuly 2025 Weekly Recap & High Conviction Trade Alerts - ulpravda.ru
Aug Opening: How strong is Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock revenue growth2025 Fundamental Recap & Long-Term Investment Growth Plans - ulpravda.ru
symbol__ Stock Quote Price and Forecast - CNN
How Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefits from tech adoptionRate Cut & Entry and Exit Point Strategies - ulpravda.ru
Is Reviva Pharmaceuticals Holdings Inc. stock trading near support levels2025 Market Outlook & High Yield Equity Trading Tips - ulpravda.ru
How strong is Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock revenue growth2025 Fundamental Recap & Long-Term Investment Growth Plans - ulpravda.ru
Will Tonix Pharmaceuticals Holding Corp. stock see insider buyingTrade Volume Report & Smart Allocation Stock Tips - ulpravda.ru
Reviva Pharmaceuticals Holdings, Inc. Announces Publication on Clinical Vocal Biomarker Data from the Recover Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia - MarketScreener
Aug PreEarnings: How Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefits from tech adoption2025 Macro Impact & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Will Reviva Pharmaceuticals Holdings Inc. stock maintain dividend yield2025 Retail Activity & Daily Profit Maximizing Trade Tips - ulpravda.ru
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia - The Manila Times
Reviva Announces Publication on Clinical Vocal Biomarker - GlobeNewswire
Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue dividend increases - ulpravda.ru
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trendBlue Chip Stock Analysis & Free Long-Term Investment Planning - ulpravda.ru
Worth Investment Trading Company Limited Shows Risk Reward Favoring Upside - Early Times
Chardan Capital assumes coverage on Reviva Pharmaceuticals stock with Buy rating - Investing.com Canada
Volatility Watch: Will Reviva Pharmaceuticals Holdings Inc Equity Warrant stock attract ESG investorsJuly 2025 Chart Watch & Verified Stock Trade Ideas - moha.gov.vn
Reviva Pharmaceuticals Holdings Inc Stock Analysis and ForecastMarket Timing Techniques & Explosive Trading Portfolio - earlytimes.in
Relief Rally in Veeram Securities Limited Stock Can It HoldVolatility Adjusted Trading & Download Our Free Trading Blueprint - earlytimes.in
What analysts say about Reviva Pharmaceuticals Holdings Inc stockBollinger Bands Signals & Try Our Free Strategy Builder Now - earlytimes.in
Technical Charts Suggest Momentum Shift in Sapphire Foods India LimitedEarnings Forecast Updates & Learn to Trade with Real-Time Feedback - earlytimes.in
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum - The Manila Times
Dow Gains 100 Points; US Durable Goods Orders Decline In October - Sahm
Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025 - ts2.tech
Reviva Pharmaceuticals' (RVPH) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Reviva Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
D Boral Capital maintains Reviva Pharmaceuticals Holdings (RVPH) buy recommendation - MSN
FDA recommends second phase 3 trial for Reviva’s schizophrenia drug By Investing.com - Investing.com Australia
Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) - MarketBeat
Reviva considers a second phase III in schizophrenia - BioWorld MedTech
Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock: plunges 50% after FDA calls for second Phase 3 schizophrenia trial - parameter.io
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Did RVPH Stock Crash 50% Today? - Stocktwits
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial By Investing.com - Investing.com Nigeria
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial - Investing.com Nigeria
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Benzinga
Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Reviva plans second Phase 3 trial after FDA feedback - TipRanks
FDA recommends second phase 3 trial for Reviva’s schizophrenia drug - Investing.com
Reviva announces regulatory update regarding the development of brilaroxazine for the treatment of schizophrenia - marketscreener.com
Reviva Pharmaceuticals Recover-2 trial projected to cost about $60 million - marketscreener.com
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia - GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock maintain growth trajectory2025 Fundamental Recap & Reliable Breakout Forecasts - Улправда
Profit Recap: Why Reviva Pharmaceuticals Holdings Inc. stock could benefit from AI revolutionIPO Watch & Smart Swing Trading Techniques - Улправда
Finanzdaten der Reviva Pharmaceuticals Holdings Inc-Aktie (RVPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):